Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

>

There was no difference between pirfenidone and placebo in the percentage of patients who experienced a serious adverse event (SAE). An SAE was reported by 35% and 33% of pirfenidone and placebo groups, respectively, in CAPACITY 2 and by 31% and 30%, respectively, in CAPACITY 1. While there was a slightly higher incidence of Grade 3 adverse events in the pirfenidone groups in both studies, there was no difference in overall Grade 4 adverse events between pirfenidone and placebo.

The pattern of adverse events was in general comparable to that observed in previous clinical studies of pirfenidone. The most common adverse events in the pirfenidone group as compared to placebo were nausea (35% vs. 18% in CAPACITY 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. 21% and 33% vs. 20%), diarrhea (25% vs. 17% and 33% vs. 21%), dyspepsia (17% vs. 9% and 21% vs. 6%), and dizziness (19% vs. 10% and 18% vs. 10%). Rash was generally mild to moderate in both studies; only 2 patients (1 in each CAPACITY study) receiving pirfenidone experienced a severe rash.

ADDITIONAL SAFETY RESULTS REPORTED

The ATS presentation reported new safety data from the CAPACITY studies pertaining to the incidence and cause of deaths, treatment discontinuations due to adverse events and laboratory tests.

Incidence and Cause of Deaths

Analysis of the incidence and cause of death revealed that fewer patients in the pirfenidone 2403 mg group compared with placebo died during the treatment period, defined as the time from the first dose until 28 days after the last dose of study treatment. In CAPACITY 1, 5.3% of patients in the pirfenidone group died during the treatment period, compared with 8.7% in the placebo group. In CAPACITY 2, 5.7% of patients in the pirfenidone group died during the treatment period, compared with 8.0% in the placebo group.

The incidence
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud ... drug design and development, partnering is an integral ... is to design new drugs and identify early ... partners to further their development. The company also ... To support this business model, Cloud Pharmaceuticals will ...
(Date:9/19/2014)... Sept. 19, 2014  Diplomat, the nation,s largest independent ... Dreyer to the Board of Directors on September ... will also serve as chair of the Audit Committee. ... of accounting, financial, compliance and operating experience in the ... served as chief financial officer, chief operating officer and ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... 19, 2011 MMIS , Inc. ... compliance solutions for the life science industry, announced the ... aggregate spend reporting solution, at the ExL Pharma 2nd ... MediSpend™ allows pharmaceutical, medical device and biotechnologies companies to ...
... Health today announced a joint venture with leading China ... to doctors in China as the country prepares for ... Wolters Kluwer Health to expand its market-leading Clinical Decision ... growing China market and creates a needed drug information ...
Cached Medicine Technology:MMIS, Inc. Launches the MediSpend™ Aggregate Spend Solution 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 3
(Date:9/19/2014)... 19, 2014 Singulair, developed by Merck, ... of leukotriene D4 (LTD4). LTD4 belongs to the family ... of cells, including mast cells and eosinophils, and which ... have determined that there are higher concentrations of Cys-LTs ... non-asthmatic individuals. The production of CysLTs is increased in ...
(Date:9/19/2014)... University researchers say a simple test that combines ... risk for developing Alzheimer,s disease in a person, ... of dementia., Faculty of Health Professor Lauren Sergio ... study asked the participants to complete four increasingly ... laptop computers. The test aimed at detecting the ...
(Date:9/19/2014)... September 19, 2014 The ... traditional Scandinavian style of eating, is making ... like Diet Doc’s medical weight loss ... and eating good food which leads to ... on teaching patients to understand how diet ...
(Date:9/19/2014)... September 19, 2014 2013 NEXT ... named a finalist for the 2014 NEXT Awards ... president Tammy Hawes has been selected as the ... The Nashville Area Chamber of Commerce and the ... to recognize the accomplishments of companies and individual ...
(Date:9/19/2014)... King of Prussia, PA (PRWEB) September 19, 2014 ... provider of Business Process Outsourcing solutions for Health ... and Managed Medicaid markets, will sponsor a Networking ... Director in the Health Industry Advisory Practice at ... 30, 2014 at the AHIP’s 2014 National Conference ...
Breaking Medicine News(10 mins):Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... ... ... WASHINGTON , March 17 The following is a statement by ... , , ...
... , TAMPA, Fla. , March 17 ... features to enhance its acclaimed study program for the ... exams. Effective immediately, 30 animated muscle tutorials, 25 interactive study ... nationwide. These features, which include narration for auditory learners, further ...
... understanding of the Skp2 gene and its relation to cellular ... can suppress tumor development in common types of cancer, researchers ... and Memorial Sloan-Kettering Cancer Center report in the journal ... cycle regulation, cell proliferation, cell growth and the formation of ...
... potentially deadly infections long has focused on looking for ways ... University of Utah and Utah State University shows that modulating ... save more lives. In a study published March ... U of U cardiologist Dean Y. Li, M.D., Ph.D., professor ...
... an indicator of more serious disease, study finds , ... bowel syndrome (IBS) aren,t at increased risk for polyps, ... disease and, in most cases, don,t require a colonoscopy, ... 10 percent to 20 percent of Americans, include recurrent ...
... WHEATON, Ill. , March 17 ... Organizational Planning, John Brady , DHA, has been ... with Disabilities Task Force. The Task Force is responsible ... changes, recommendations, and innovations may be needed to enhance ...
Cached Medicine News:Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Disabling Skp2 gene helps shut down cancer growth 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Colonoscopy Not Needed for Most With Irritable Bowel Syndrome 2Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: